Recent FDA approvals may help improve outcomes for pediatric patients with rheumatic diseases, according to a report from Cincinnati Children’s Hospital Medical Center. Hermine Brunner, MD, MSc, MBA, Director of the Division of Rheumatology at Cincinnati Children’s, presented research on the topic at the Congress of Clinical Rheumatology West 2023 annual meeting. Drugs can only be approved for pediatric patients once sufficient evidence of their safety and efficacy is demonstrated in adult patients. For her presentation, Dr. Brunner and colleagues reviewed the benefit of belimumab, golimumab, tofacitinib, secukinumab, and ustekinumab in pediatric patients—all of which have been approved in the last 4 years. They noted that belimumab was approved for pediatric patients with systemic lupus erythematosus in 2019 and for pediatric patients with lupus nephritis in 2022 after clinical trials showed that the agent had similar efficacy in both adult and pediatric patients. Further, golimumab and tofacitinib, both approved in 2020, were shown to be effective in pediatric patients with polyarticular juvenile idiopathic arthritis. In 2021 and 2022, secukinumab and ustekinumab, respectively, were approved for use in pediatric patients with psoriatic arthritis after providing a notable reduction in flares in clinical trials.